Related Experiment Video
Updated: Jul 3, 2026
13:14
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Fully human antibodies from transgenic mouse and phage display platforms
1Medarex, Milpitas, CA 95035, United States. nlonberg@medarex.com
Current Opinion in Immunology
|July 9, 2008
Summary
Fully human monoclonal antibodies (MAbs) from phage display or transgenic mice offer low immunogenicity therapeutics. Lead optimization is more common in phage display MAb development, though both platforms yield well-tolerated treatments.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Technologies for generating fully human monoclonal antibodies (MAbs) have advanced significantly.
- These human MAbs offer a low-immunogenicity alternative to rodent-derived antibodies for therapeutic use.
Purpose of the Study:
- To review the development and clinical status of fully human therapeutic MAbs.
- To compare the phage display and transgenic mouse platforms used for MAb generation.
Main Methods:
- Analysis of existing clinical data for fully human therapeutic MAbs.
- Review of drug discovery processes associated with different MAb generation platforms.
Main Results:
- Two fully human MAbs (adalimumab, panitumumab) are marketed, with dozens more in clinical trials.
- Both phage display and transgenic mouse platforms have produced well-tolerated therapeutic antibodies.
- Lead optimization appears more frequently applied to phage display-derived candidates.
Conclusions:
- Fully human MAbs generated via phage display and transgenic mouse platforms are significant sources of therapeutic antibodies.
- Current clinical data do not definitively distinguish between the platforms in terms of efficacy or tolerability.
- Differences in lead optimization strategies may exist between the two platforms.
